Chalcone Derivatives: Promising Starting Points for Drug Design

Medicinal chemists continue to be fascinated by chalcone derivatives because of their simple chemistry, ease of hydrogen atom manipulation, straightforward synthesis, and a variety of promising biological activities. However, chalcones have still not garnered deserved attention, especially considering their high potential as chemical sources for designing and developing new effective drugs. In this review, we summarize current methodological developments towards the design and synthesis of new chalcone derivatives and state-of-the-art medicinal chemistry strategies (bioisosterism, molecular hybridization, and pro-drug design). We also highlight the applicability of computer-assisted drug design approaches to chalcones and address how this may contribute to optimizing research outputs and lead to more successful and cost-effective drug discovery endeavors. Lastly, we present successful examples of the use of chalcones and suggest possible solutions to existing limitations.

[1]  T. Klabunde Chemogenomic approaches to drug discovery: similar receptors bind similar ligands , 2007, British journal of pharmacology.

[2]  Alexander Tropsha,et al.  Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation , 2016, J. Chem. Inf. Model..

[3]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[4]  Daniela Schuster,et al.  Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling. , 2015, Methods.

[5]  E. Wong The role of chalcones and flavanones in flavonoid biosynthesis , 1968 .

[6]  F. V. van Heerden,et al.  Application of the Suzuki-Miyaura Reaction in the Synthesis of Flavonoids , 2013, Molecules.

[7]  N. Meanwell Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.

[8]  M. Kikuchi,et al.  Anti-allergic Activity of Naringenin Chalcone from a Tomato Skin Extract , 2004, Bioscience, biotechnology, and biochemistry.

[9]  E. LaVoie,et al.  Bioisosterism: A Rational Approach in Drug Design. , 1996, Chemical reviews.

[10]  Alexander Tropsha,et al.  Curation of chemogenomics data. , 2015, Nature chemical biology.

[11]  Muriel Hachet-Haas,et al.  Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo. , 2012, ACS medicinal chemistry letters.

[12]  Shinji Ohta,et al.  C-geranylated chalcones from the stems of Angelica keiskei with superoxide-scavenging activity. , 2008, Journal of natural products.

[13]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[14]  Kai Huang,et al.  PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..

[15]  Subha Kalyaanamoorthy,et al.  Modelling and enhanced molecular dynamics to steer structure-based drug discovery. , 2014, Progress in biophysics and molecular biology.

[16]  C. Nakamura,et al.  Recent advances in leishmaniasis treatment. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[17]  Diogo Santos-Martins,et al.  Receptor-based virtual screening protocol for drug discovery. , 2015, Archives of biochemistry and biophysics.

[18]  J. Sikorski,et al.  Recent advances in therapeutic chalcones , 2004 .

[19]  John B. O. Mitchell Machine learning methods in chemoinformatics , 2014, Wiley interdisciplinary reviews. Computational molecular science.

[20]  David S. Goodsell,et al.  The RCSB Protein Data Bank: views of structural biology for basic and applied research and education , 2014, Nucleic Acids Res..

[21]  E. Barreiro,et al.  Molecular hybridization: a useful tool in the design of new drug prototypes. , 2007, Current medicinal chemistry.

[22]  D. Ferry,et al.  [3H]-Nitrendipine, a potent calcium antagonist, binds with high affinity to cardiac membranes. , 1981, Arzneimittel-Forschung.

[23]  Leonardo L. G. Ferreira,et al.  Molecular Docking and Structure-Based Drug Design Strategies , 2015, Molecules.

[24]  Virander S. Chauhan,et al.  Mechanism of malarial haem detoxification inhibition by chloroquine. , 2001, The Biochemical journal.

[25]  S. Ducki Antimitotic chalcones and related compounds as inhibitors of tubulin assembly. , 2009, Anti-cancer agents in medicinal chemistry.

[26]  A. Magalska,et al.  Ciprofloxacin inhibits proliferation and promotes generation of aneuploidy in Jurkat cells. , 2010, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[27]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[28]  Patrick Gizzi,et al.  Small Neutralizing Molecules to Inhibit Actions of the Chemokine CXCL12* , 2008, Journal of Biological Chemistry.

[29]  Ruibo Wu,et al.  Computational Design of a Time-Dependent Histone Deacetylase 2 Selective Inhibitor , 2014, ACS chemical biology.

[30]  C. Dumontet Mechanisms of action and resistance to tubulin-binding agents , 2000, Expert opinion on investigational drugs.

[31]  U. Rashid,et al.  Structure based medicinal chemistry-driven strategy to design substituted dihydropyrimidines as potential antileishmanial agents. , 2016, European journal of medicinal chemistry.

[32]  Cristiano Ruch Werneck Guimarães,et al.  MM-GB/SA Rescoring of Docking Poses in Structure-Based Lead Optimization , 2008, J. Chem. Inf. Model..

[33]  M. Jasamai,et al.  Synthesis and biological evaluation of chalcone derivatives (mini review). , 2012, Mini reviews in medicinal chemistry.

[34]  C. Wermuth,et al.  Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998) , 1998 .

[35]  S. Kazda,et al.  Pharmacological studies of the antihypertensive effect of nitrendipine. , 1981, Arzneimittel-Forschung.

[36]  F. Sarkar,et al.  Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. , 2003, International journal of oncology.

[37]  D. Siegel Comprehensive Organic Name Reactions and Reagents, Volume 1−3 , 2010 .

[38]  N. Lajis,et al.  Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-κB nuclear translocation and Iκ-B phosphorylation in RAW 264.7 macrophage cells , 2007 .

[39]  M. Chung,et al.  The Prodrug Approach: A Successful Tool for Improving Drug Solubility , 2015, Molecules.

[40]  R J Fletterick,et al.  Structure-based design of parasitic protease inhibitors. , 1996, Bioorganic & medicinal chemistry.

[41]  S. Sundar,et al.  Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani. , 2010, The Journal of antimicrobial chemotherapy.

[42]  K. Srivastava,et al.  Synthesis and in vitro evaluation of new chloroquine-chalcone hybrids against chloroquine-resistant strain of Plasmodium falciparum. , 2012, Bioorganic & medicinal chemistry letters.

[43]  Alexander Tropsha,et al.  Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS , 2017, J. Chem. Inf. Model..

[44]  N. Sahu,et al.  Exploring pharmacological significance of chalcone scaffold: a review. , 2012, Current medicinal chemistry.

[45]  Jahan B Ghasemi,et al.  Methods and applications of structure based pharmacophores in drug discovery. , 2013, Current topics in medicinal chemistry.

[46]  S. Amslinger,et al.  Reactivity assessment of chalcones by a kinetic thiol assay. , 2013, Organic & biomolecular chemistry.

[47]  Xiao Yu,et al.  Protein Flexibility in Docking-Based Virtual Screening: Discovery of Novel Lymphoid-Specific Tyrosine Phosphatase Inhibitors Using Multiple Crystal Structures , 2015, J. Chem. Inf. Model..

[48]  Paolo Massimo Buscema,et al.  Similarity Coefficients for Binary Chemoinformatics Data: Overview and Extended Comparison Using Simulated and Real Data Sets , 2012, J. Chem. Inf. Model..

[49]  M. Kumar,et al.  Synthesis and antihyperlipidemic activity of novel coumarin bisindole derivatives. , 2010, Bioorganic & medicinal chemistry letters.

[50]  Vladimir Vapnik,et al.  The Nature of Statistical Learning , 1995 .

[51]  D. Ribatti,et al.  Antivascular and antitumor properties of the tubulin-binding chalcone TUB091 , 2016, Oncotarget.

[52]  F. Chang,et al.  Continuous-Flow Synthesis of Deuterium-Labeled Antidiabetic Chalcones: Studies towards the Selective Deuteration of the Alkynone Core , 2016, Molecules.

[53]  U. Schultz-Ehrenburg,et al.  [Controlled study of increasing venous tone in primary varicose veins by oral administration of Ruscus aculeatus and trimethylhespiridinchalcone]. , 1987, Zeitschrift fur Hautkrankheiten.

[54]  G. Tsourouflis,et al.  Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. , 2017, Anticancer research.

[55]  Maria A Miteva,et al.  Pan-assay interference compounds (PAINS) that may not be too painful for chemical biology projects. , 2017, Drug discovery today.

[56]  G. Moreau,et al.  Rational approach to drug design , 2008 .

[57]  Alexander Tropsha,et al.  Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.

[58]  Synthesis and biological evaluation of novel hybrid chalcone derivatives as vasorelaxant agents. , 2010, European journal of medicinal chemistry.

[59]  G. Bhatia,et al.  Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents. , 2014, European journal of medicinal chemistry.

[60]  M. Rueping,et al.  Continuous-flow hydration–condensation reaction: Synthesis of α,β-unsaturated ketones from alkynes and aldehydes by using a heterogeneous solid acid catalyst , 2011, Beilstein journal of organic chemistry.

[61]  S. Horwitz,et al.  Targeting histone deacetylases in T-cell lymphoma , 2017, Leukemia & lymphoma.

[62]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[63]  F. J. Luque,et al.  Protein flexibility and ligand recognition: challenges for molecular modeling. , 2011, Current topics in medicinal chemistry.

[64]  Charles H Reynolds,et al.  Impact of computational structure-based methods on drug discovery. , 2014, Current pharmaceutical design.

[65]  A. Tafi,et al.  Pharmacophore modelling: a forty year old approach and its modern synergies. , 2011, Current medicinal chemistry.

[66]  Anne E Carpenter,et al.  Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening. , 2016, Journal of medicinal chemistry.

[67]  J. Chen,et al.  Design, Synthesis, and Biological Evaluation of Prenylated Chalcones as Vasorelaxant Agents , 2009, Archiv der Pharmazie.

[68]  N. Duran,et al.  Synthesis and anti-proliferative activity of fluoro-substituted chalcones. , 2016, Bioorganic & medicinal chemistry letters.

[69]  Mark McGann,et al.  FRED and HYBRID docking performance on standardized datasets , 2012, Journal of Computer-Aided Molecular Design.

[70]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.

[71]  C. G. Mohan,et al.  Antiobesity and lipid lowering effects of Glycyrrhiza chalcones: experimental and computational studies. , 2011, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[72]  Suengmok Cho,et al.  Isoliquiritigenin, a chalcone compound, is a positive allosteric modulator of GABAA receptors and shows hypnotic effects. , 2011, Biochemical and biophysical research communications.

[73]  M. R. Senger,et al.  Filtering promiscuous compounds in early drug discovery: is it a good idea? , 2016, Drug discovery today.

[74]  Haiyan Chen,et al.  Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking , 2014, Acta Pharmacologica Sinica.

[75]  Markus Sitzmann,et al.  Software and resources for computational medicinal chemistry. , 2011, Future medicinal chemistry.

[76]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[77]  Y. Wu,et al.  Highly Selective Continuous-Flow Synthesis of Potentially Bioactive Deuterated Chalcone Derivatives. , 2015, ChemPlusChem.

[78]  Ricardo L. Mancera,et al.  Ligand-Protein Docking with Water Molecules , 2008, J. Chem. Inf. Model..

[79]  J. Deslypere Clinical implications of the biopharmaceutical properties of fluvastatin. , 1994, The American journal of cardiology.

[80]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[81]  K. Sonogashira,et al.  A Convenient Synthesis of Ethynylarenes and Diethynylarenes , 1980 .

[82]  Thomas E. Exner,et al.  pKa based protonation states and microspecies for protein–ligand docking , 2010, J. Comput. Aided Mol. Des..

[83]  Emil Alexov,et al.  The role of protonation states in ligand-receptor recognition and binding. , 2013, Current pharmaceutical design.

[84]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[85]  W. Hagmann,et al.  The many roles for fluorine in medicinal chemistry. , 2008, Journal of medicinal chemistry.

[86]  Dwipen Kakati,et al.  Microwave assisted solvent free synthesis of 1,3-diphenylpropenones , 2011, Chemistry Central journal.

[87]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[88]  C. Xing,et al.  Diverse Molecular Targets for Chalcones with Varied Bioactivities , 2015, Medicinal chemistry.

[89]  A. Nadhman,et al.  Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives. , 2013, Future medicinal chemistry.

[90]  J. Schwöbel,et al.  Prediction of michael-type acceptor reactivity toward glutathione. , 2010, Chemical research in toxicology.

[91]  Eugene N Muratov,et al.  Per aspera ad astra: application of Simplex QSAR approach in antiviral research. , 2010, Future medicinal chemistry.

[92]  Peter Ertl,et al.  Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization , 2010, Molecular informatics.

[93]  B. Grygiel-Górniak Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review , 2014, Nutrition Journal.

[94]  Jung-Hsin Lin Accommodating protein flexibility for structure-based drug design. , 2011, Current topics in medicinal chemistry.

[95]  Michelle L Coote,et al.  Molecular dynamics-driven drug discovery: leaping forward with confidence. , 2017, Drug discovery today.

[96]  Bruce Tidor,et al.  Systematic placement of structural water molecules for improved scoring of protein-ligand interactions. , 2011, Protein engineering, design & selection : PEDS.

[97]  Kunal Roy,et al.  How far can virtual screening take us in drug discovery? , 2013, Expert opinion on drug discovery.

[98]  Arieh Warshel,et al.  Progress in ab initio QM/MM free-energy simulations of electrostatic energies in proteins: accelerated QM/MM studies of pKa, redox reactions and solvation free energies. , 2009, The journal of physical chemistry. B.

[99]  Enrico Glaab,et al.  Building a virtual ligand screening pipeline using free software: a survey , 2015, Briefings Bioinform..

[100]  L. M. Lima,et al.  Bioisosterism: a useful strategy for molecular modification and drug design. , 2005, Current medicinal chemistry.

[101]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[102]  Fatih Köksal,et al.  New drugs for the treatment of Mycobacterium tuberculosis infection. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[103]  Vladimir N. Vapnik,et al.  The Nature of Statistical Learning Theory , 2000, Statistics for Engineering and Information Science.

[104]  C. Andrade,et al.  QSAR and QM/MM approaches applied to drug metabolism prediction. , 2012, Mini reviews in medicinal chemistry.

[105]  R. Beltramino,et al.  An Open-Label, Randomized Multicenter Study Comparing the Efficacy and Safety of Cyclo 3 Fort® Versus Hydroxyethyl Rutoside in Chronic Venous Lymphatic Insufficiency , 2000, Angiology.

[106]  K. Tominaga,et al.  Sofalcone, a gastroprotective drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori: A randomized controlled comparative trial with cimetidine, an H2‐receptor antagonist , 2010, Journal of gastroenterology and hepatology.

[107]  C. Andrade,et al.  Computer-aided discovery of two novel chalcone-like compounds active and selective against Leishmania infantum. , 2017, Bioorganic & medicinal chemistry letters.

[108]  R. Ertan,et al.  Chemical and Structural Properties of Chalcones I , 2014 .

[109]  Luigi Vaccaro,et al.  Polystyryl-supported TBD as an efficient and reusable catalyst under solvent-free conditions. , 2004, Chemical communications.

[110]  M. Banach,et al.  The role of fibrate treatment in dyslipidemia: an overview. , 2013, Current pharmaceutical design.

[111]  Eugene Muratov,et al.  QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity. , 2017, European journal of medicinal chemistry.

[112]  J. Bajorath,et al.  State-of-the-art in ligand-based virtual screening. , 2011, Drug discovery today.

[113]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[114]  L. Dahners,et al.  Effect of ciprofloxacin on the proliferation of osteoblast‐like MG‐63 human osteosarcoma cells in vitro , 1998, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[115]  Teruaki Akao,et al.  Isoliquiritigenin, one of the antispasmodic principles of Glycyrrhiza ularensis roots, acts in the lower part of intestine. , 2007, Biological & pharmaceutical bulletin.

[116]  J. Schwabe,et al.  Targeting Class I Histone Deacetylases in a "Complex" Environment. , 2017, Trends in pharmacological sciences.

[117]  E. Proschak,et al.  Structure‐Based Pharmacophores for Virtual Screening , 2011, Molecular informatics.

[118]  C. Andrade,et al.  Modern approaches to accelerate discovery of new antischistosomal drugs , 2016, Expert opinion on drug discovery.

[119]  Ruibo Wu,et al.  A proton-shuttle reaction mechanism for histone deacetylase 8 and the catalytic role of metal ions. , 2010, Journal of the American Chemical Society.

[120]  Steven W. Muchmore,et al.  High-Throughput Calculation of Protein-Ligand Binding Affinities: Modification and Adaptation of the MM-PBSA Protocol to Enterprise Grid Computing , 2006, J. Chem. Inf. Model..

[121]  Brian S. Fulton,et al.  Glossary of Terms Used in Medicinal Chemistry , 2014 .

[122]  Vivek Asati,et al.  Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives. , 2015, European journal of medicinal chemistry.

[123]  D. Rognan Chemogenomic approaches to rational drug design , 2007, British journal of pharmacology.

[124]  Prasenjit Mukherjee,et al.  An overview of molecular fingerprint similarity search in virtual screening , 2016, Expert opinion on drug discovery.

[125]  Zhilong Xiu,et al.  Rescoring ligand docking poses. , 2010, Current opinion in drug discovery & development.

[126]  N. Lawrence,et al.  The interaction of chalcones with tubulin. , 2000, Anti-cancer drug design.

[127]  J. Dearden,et al.  QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.

[128]  T. Müller,et al.  Coupling-isomerization synthesis of chalcones. , 2006, Chemistry.

[129]  Adrià Cereto-Massagué,et al.  Molecular fingerprint similarity search in virtual screening. , 2015, Methods.

[130]  C. Xia,et al.  Efficient Coupling Reactions of Arylalkynes and Aldehydes Leading to the Synthesis of Enones , 2004 .

[131]  K. Park,et al.  Quantitative analysis of phenolic metabolites from different parts of Angelica keiskei by HPLC-ESI MS/MS and their xanthine oxidase inhibition. , 2014, Food chemistry.

[132]  X. Daura,et al.  Parametrization of aliphatic CHn united atoms of GROMOS96 force field , 1998 .

[133]  R. Yunes,et al.  Biological Evaluation of Chalcones and Analogues as Hypolipidemic Agents , 2006, Archiv der Pharmazie.

[134]  C. A. Fraga Drug hybridization strategies: before or after lead identification? , 2009, Expert opinion on drug discovery.

[135]  P. Kumar,et al.  Leishmania donovani pteridine reductase 1: biochemical properties and structure-modeling studies. , 2008, Experimental parasitology.

[136]  Markus A Lill,et al.  Induced fit docking, and the use of QM/MM methods in docking. , 2013, Drug discovery today. Technologies.

[137]  Yuko Okamoto,et al.  QM/MM free energy simulations: recent progress and challenges , 2016, Molecular simulation.

[138]  Stefano Forli,et al.  Virtual screening with AutoDock: theory and practice , 2010, Expert opinion on drug discovery.

[139]  E. Rubinstein,et al.  In vitro effects of ciprofloxacin and pefloxacin on growth of normal human hematopoietic progenitor cells and on leukemic cell lines. , 1989, The Journal of pharmacology and experimental therapeutics.

[140]  Stephani Joy Y Macalino,et al.  Role of computer-aided drug design in modern drug discovery , 2015, Archives of Pharmacal Research.

[141]  Carmenza Spadafora,et al.  Malarial hemozoin: from target to tool. , 2014, Biochimica et biophysica acta.

[142]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[143]  Guigang Zhang,et al.  Deep Learning , 2016, Int. J. Semantic Comput..

[144]  Yi-Ping Phoebe Chen,et al.  Structure-based drug design to augment hit discovery. , 2011, Drug discovery today.

[145]  C. Wan,et al.  Synthesis and biological evaluation of novel hybrid compounds between chalcone and piperazine as potential antitumor agents , 2016 .

[146]  Carolina H Andrade,et al.  Assessing the performance of 3D pharmacophore models in virtual screening: how good are they? , 2013, Current topics in medicinal chemistry.

[147]  Donald J Abraham,et al.  Structure-based drug design strategies in medicinal chemistry. , 2009, Current topics in medicinal chemistry.

[148]  P. Martorana,et al.  Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor , 1995, British journal of pharmacology.

[149]  Anne E Carpenter,et al.  QSAR-Driven Discovery of Novel Chemical Scaffolds Active against Schistosoma mansoni , 2016, J. Chem. Inf. Model..

[150]  Amedeo Caflisch,et al.  Quantum mechanical methods for drug design. , 2010, Current topics in medicinal chemistry.

[151]  R. Beltramino,et al.  An open-label, randomised multicentre study comparing the efficacy and safety of CYCLO 3 FORT versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. , 1999, International angiology : a journal of the International Union of Angiology.

[152]  A. Brancale,et al.  Design, synthesis, and biological evaluation of thiophene analogues of chalcones. , 2008, Bioorganic & medicinal chemistry.

[153]  E. Lionta,et al.  Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances , 2014, Current topics in medicinal chemistry.

[154]  J. Berman,et al.  Advances in leishmaniasis , 2005, The Lancet.

[155]  S. Christensen,et al.  Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania , 1993, Antimicrobial Agents and Chemotherapy.

[156]  R. Fruttero,et al.  A new class of furoxan derivatives as NO donors: mechanism of action and biological activity , 1995, British journal of pharmacology.

[157]  Simon Feldbaek Nielsen,et al.  Antibacterial chalcones--bioisosteric replacement of the 4'-hydroxy group. , 2004, Bioorganic & medicinal chemistry.

[158]  A Burger,et al.  Isosterism and bioisosterism in drug design. , 1991, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.